Valbiotis and Nestlé Health Science terminate their licensing agreement

The company Valbiotis announced the end of its licensing and supply contract with Nestlé Health Science. This agreement, concluded on June 4, 2024, allows Valbiotis to recover all rights to its food supplement, TOTUM•63.

From now on, Valbiotis can launch TOTUM•63 in France in the first half of 2025 and plan international partnerships. The company disposes of the intellectual property, including patents and clinical data, without reimbursement of the 12.75 million Swiss francs paid by Nestlé Health Science.

With cash of 25 million euros at the end of 2023, Valbiotis plans to strengthen its commercial strategy for TOTUM•63. This newfound freedom allows the company to negotiate new licensing agreements and target new markets.

At the same time, Valbiotis continues to develop its other products, such as TOTUM•854 for blood pressure and TOTUM•448 for fatty liver.